BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 23928062)

  • 1. B cell receptor signaling in chronic lymphocytic leukemia.
    Burger JA; Chiorazzi N
    Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
    ten Hacken E; Burger JA
    Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
    Ten Hacken E; Burger JA
    Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
    Patton JT; Woyach JA
    Semin Hematol; 2024 Apr; 61(2):100-108. PubMed ID: 38749798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Lymphocytic Leukemia: Disease Biology.
    Koehrer S; Burger JA
    Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
    Ten Hacken E; Gounari M; Ghia P; Burger JA
    Leukemia; 2019 Feb; 33(2):287-298. PubMed ID: 30555163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
    Davids MS; Brown JR
    Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
    Koehrer S; Burger JA
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
    ten Hacken E; Burger JA
    Clin Cancer Res; 2014 Feb; 20(3):548-56. PubMed ID: 24323900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
    Seda V; Mraz M
    Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.
    Efremov DG; Gobessi S; Longo PG
    Autoimmun Rev; 2007 Dec; 7(2):102-8. PubMed ID: 18035318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
    Wiestner A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
    Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
    Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
    Burger JA
    Curr Opin Oncol; 2012 Nov; 24(6):643-9. PubMed ID: 22960555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.